CAR-T in English means: 1) Model-T small automobile; 2) cart, e.g. shopping cart
I am not sure if it's a blow to only juno or the whole sub-sector
Have not seen a pivotal phase III trial with so few updates. Last updates was 2015_05_27, before then was 2014_10_27. Intervals were half year and then 1 year. Previous normal update interval was 1 week. The company didn't like to talk about enrollment details either.
We knew that cometriq dosage was not optimal. The question is whether prescription of Cabometyx to MTC patients is regarded as Off-lable and needs approval?
RCC is almost done, just waiting for OS conclusion. HCC enrollment had been slowed down for more than one year. No other phaseIII is running by now. What will MMM be going to tell us on next PR? fast celestial, other thyroid cancers, triple negative breast cancer, or XL888?
It's so boring, please do some PR. Like "we have submitted all documents.", "we are done enrollment for CELESTIAL"
If you cannot, how about "Our CEO has been recognized as scientist with best hair style in biotech industry by Hair Stylists magazine".
Anyway, It seems EXEL has slowed down HCC enrollment since last Octorber. Don't know it's due to tight budget or human resource.
NCT01954745 is about to finish. It's one indication that cabo may fit in for EGFR and c-Met mutations.I am wondering if it's economically viable to run a phase III trial for 2nd/3rd line for a rare cancer, since if phase II is good doctors will have to prescribe it without other better choices. MTC was another story because it was kinda like verification of concepts. Or we should be going after bigger indications first?
It's an open label trial with research in mind. So I guess the interim analysis are running everyday implicitly.
Japanese trial enrollment is so quick. A phase II trial of CS-3150 needs to recruit 400 patients, started on January19, and finished enrollment at May7, expecting Primary Completion Date to be December. Why seriously did it take so long to start?